Cargo can't replicate firi-cel's academic success
Firce-1 is scrapped after showing dismal response rates and patient deaths.
Jefferies 2024 – Cargo tries again with an old idea
A CD22-directed Car that has had several owners will next year deliver its most important dataset.
Regeneron gets another bispecific blow
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
Pfizer hopes not to get stung
New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.
Sana shelves its in vivo Car-T
The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.
